Amendment: Correction of ISIN in prospectus NOT FOR

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Nov 24, 2015 at 2:15 AM

Amendment: Correction of ISIN in prospectus

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONS. The ISIN for the interim shares (Sw: betald tecknad aktie, BTA) and the subscription rights (Sw: teckningsrätt, TR) in the prospectus regarding Vigmed Holding AB’s (publ) (“Vigmed” or the “Company”) rights issue has been interchanged. The correct information for each security is listed below: ISIN share: SE0005034576 ISIN interim share (BTA): SE0007730601 ISIN subscription right (teckningsrätt): SE0007730593 For more information, please contact: Henrik Olsen, CEO Vigmed, telephone +46 763 49 73 64, e-mail ho@vigmed.com or Lennart Holm, Chairman of the Board, telephone +46 706 30 85 62. Vigmed discloses the information in this press release pursuant to the Swedish Securities Markets Act. The information was provided for public release on 24 November 2015 at 08:00 CET. Important information This press release is not an offer regarding shares or other securities issued by Vigmed Holding AB (publ) (“Vigmed” or the “Company”). This press release may not be distributed in or into the United States, Canada, Japan, Australia or in any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law. Nor may the information in this press release be forwarded or reproduced in a manner that contravenes such restrictions or gives cause to such requirements. No securities issued by the Company have been or will be registered under the United States Securities Act of 1933, as amended (“Securities Act”) and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act. No public offering will be made in the United States. In member states within the European Economic Area (EEA) (other than Sweden) which have implemented Directive 2003/71/EC (the “Prospectus Directive”), this press release is directed only at qualified investors as defined in the Prospectus Directive. This press release may contain certain forward-looking statements that reflect the Company’s current views on future events as well as financial and operational performance. Words such as “intend”, “assess”, “expect”, “may”, “plan”, “believe”, “estimate” and other expressions entailing indications or predictions of future development or trends, and which are not based on historical facts, constitute forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements information is not a guarantee of future results or performance, and the actual outcome may differ materially from the information set forth in the forward -looking statements. A prospectus prepared in accordance with the Prospectus Directive have been published on 20 November 2015 and is, with certain restrictions, available at www.vigmed.com. Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood -borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 500 shareholders. Remium Nordic AB is the Company’s Certified Advisor. Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Steel Dynamics Gears Up for Q3 2026 Earnings Update

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Aspen Dental Brings Comprehensive Care to Whiteville

Bringing Dentistry Closer to Home Now, Whiteville's dental game just got a power-up, with Aspen Dental setting up shop in town. This isn't just another practice popping up—it's a full-on dental hub offering everything from regular cleanings to emergency tooth fixes. And let’s face it, this area's diverse population needs it. The Man Behind the Chair Guess who’s at...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Protecting Your Family on Halloween: Safety Tips

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Teamsters Secure Landmark Deal for SF Parking Workers

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...

Raken Debuts Change Orders: A Game-Changer for Builds

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

Hexaware Teams with Anthropic for Game-Changing AI Move

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

Webull Faces Legal Scrutiny Over Chinese Ties

The Unfolding Drama for Webull Shareholders When you see a ticker like NASDAQ:BULL rolling off your tongue these days, it’s not just about stock prices anymore—it's a whole saga wrapped in legal and geopolitical spice. Following the recent uproar from a House China committee report, Webull found itself thrust into the spotlight for all the wrong reasons. That report...

Rutter Mills Secures $13M in Virginia Injury Cases

The Stakes in Virginia When you drop nine successful injury cases on the scales and they tip over $13 million, that's a story worth dissecting. The two top dogs at Rutter Mills certainly know how to make a splash in the legal puddle, don't they? We're talking about attorneys Adam H. Lotkin and Georgina D. Montgomery here, the legal eagles behind these jaw-dropping...

Lupin Secures FDA Nod for Key Injectable Drug

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...